particularly interesting to note that in this situation the PCR always results in a single band of the 685bp, representing the expression of the isoform lacking exon 5. This indicates that a small number of cells, below the FISH detection level, are exclusively expressing the short isoform. This single-isoform expression observed in this work was reported previously by Takatsuki et al., 4 who examined the expression of PML/RAR-a in hematopoietic colonies in five APL patients by RT-PCR analysis. They described three different types of colonies: those expressing only the 780 bp fragment (equivalent to the long isoform), those expressing only the 640 bp fragment (equivalent to the short isoform) and those expressing both fragments, suggesting that alternative splicing was clonally determined in each colony. In addition, our data showed that the isoform lacking exon 5 disappeared last during treatment ( Figure 2 , patients 1-5) and appeared around relapse periods ( Figure 2 , patients [5] [6] [7] [8] [9] . This suggests that the clones expressing the long isoform had responded to therapy and that their numbers had decreased, while cells expressing the PML-RARA isoform lacking exon 5 are more resistant to therapy and therefore remain detectable. As exon 5 is part of the a-helical domain, it was suggested previously that its absence may influence response to treatment. 4 Moreover, the fact that a small number of cells possess a high level of expression of a specific isoform suggests that this isoform is of an aggressive nature.
To conclude, in this work we utilized nested RT-PCR to monitor the different PML-RARA fusion isoforms and discovered that an isoform lacking exon 5 can be differentiated from other positive results using set I primers as designed by Borrow et al. 5 We suggest that clinical laboratories analyzing PML-RARA patients may benefit from identifying the different isoforms, giving additional information to the clinicians. We have shown that this transcript disappears last under therapy initiation and reappears first around relapse periods, suggesting the persistence of such a transcript.
Many types of cancers are currently treated with high-dose chemotherapy, which affects all (rapidly) dividing cells, including hematopoietic progenitor cells (HPCs). Therefore, even after stem cell transplantation, patients often suffer from a period of pancytopenia. Anemia and leukopenia, in this respect, can be successfully treated with Epo and G-CSF, respectively, by inducing a faster recovery of hemoglobin and neutrophil levels. Several attempts have been undertaken to shorten the period of thrombocytopenia by co-transplantation of autologous megakaryocytes (MKs) expanded from CD34 þ HPCs, but the effect of this treatment was variable and if present, minimal.
1-4 However, the MK expansion protocols used in these clinical trials vary considerably and optimization of the composition of the transplant may therefore increase the clinical benefit of co-transplantation of expanded MKs. We therefore investigated whether MKs generated from mobilized peripheral blood (MPB) CD34 þ could induce fast platelet production when combined with unmanipulated CD34 þ cells after transplantation in the nonobese diabetic/severe combined immunodeficiency (NOD/ SCID) mouse. For this purpose, CD34 þ cells were cultured for 7 days with 100 ng ml À1 thrombopoietin (Tpo) and 10 ng ml interleukin-1b (IL-1b), a cytokine cocktail, previously shown to efficiently generate MK progenitors and mature MKs (up to 32N) in our lab. 5 The NOD/SCID mouse model has long been accepted as a model for human hematopoiesis. 6 Transplantation of human MPB CD34
þ cells can result in high levels of engraftment and Please note that the author names listed in the Advance Online Publication (AOP) version of this article were listed incorrectly. These have now been corrected in this print version.
Letters to the Editor differentiation along multiple lineages in the bone marrow (BM) of NOD/SCID mice. 7 In two previous studies, 8, 9 in which human platelet formation after transplantation of MPB CD34 
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þ . Sublethally irradiated (3.5 Gy) NOD/SCID mice were intravenously transplanted with grafts composed of different combinations of uncultured and/or cultured cells ( Table 1 ). The kinetics of human platelet formation from day 3 till day 28 after transplantation is shown in Figure 1a . The absolute number of human platelets in mouse blood was determined with a flow cytometric assay. By titration of human platelets in mouse blood we established a detection threshold of 1 Â 10 4 human platelets ml À1 blood (data not shown). Three mice that were irradiated but not transplanted, served as internal controls.
Three days after transplantation, human platelets were detected in all groups receiving grafts containing all cells from the megakaryocyte cultures that were initiated with at least 2.25 Â 10 6 CD34 þ cells ( ¼ 50%). The blood of mice from group 3 (receiving 100% uncultured cells plus 100% expanded cells), group 4 (50% uncultured plus 50% expanded cells) and group 5 (100% expanded) contained a median number of human platelets per ml of 3.3 Â 10 4 , 2.3 Â 10 4 and 3.9 Â 10 4 , respectively ( Figure 1b) . The difference between these groups and group 1 (100% uncultured) and group 2 (90% uncultured and 10% expanded), was significant. The median number of platelets between group 4 (50% uncultured plus 50% expanded cells) and group 5 (100% expanded) was significantly different at this time point as well (Figure 1b) . At day 7 human platelets were also detected in the blood of mice from group 2 receiving MKs generated from 0.45 Â 10 6 CD34 þ cells ( ¼ 10%; Figure 1a ). Group 1 did not show human platelet formation at this point. At day 10 after transplantation and onwards, human platelets could also be detected in the blood of the mice from this group. This indicates that between day 7 and 10 the transplanted HPCs had differentiated into MKs and started to produce platelets. After day 14, there was no difference in the number of human platelets detected between mice receiving at least 4.05 Â 10 6 uncultured CD34 þ cells, that is groups 1, 2 and 3 (median of 1.7 Â 10 7 , 1.0 Â 10 7 and 2.0 Â 10 7 ml À1 , respectively; Figure 1c) ) was still detected. However, at day 21 the levels of platelets detected in the mice of these groups were not significantly different (median of 2.0 Â 10 7 ml À1 and 1.1 Â 10 7 ml À1 , respectively). The mice in group 5, receiving grafts composed of only cultured cells, showed significantly lower levels of human platelets at day 14 (median of Table 1 Grafts consisting of combinations of uncultured and/or 7-day expanded CD34 Letters to the Editor 6.0 Â 10 5 ml À1 ) than the mice from groups 1 to 3 (Figure 1c ), and this number declined thereafter. Group 4 did not show significantly more human platelets at day 14 after transplantation, but from day 21 the difference between groups 4 and 5 was significant.
Functionality of the human platelets produced in the NOD/SCID mice was tested by incubation with thrombinreceptor-activating peptide (TRAP-6). The resulting increase in human CD62P surface expression indicated that the human platelets formed in NOD/SCID mice, transplanted with cultured or uncultured cells, were functional ( Supplementary  Figure 1a and 1b) .
Other groups have investigated the ability of MKs generated from cord blood (CB) CD34 þ cells to form platelets in NOD/ SCID mice. [10] [11] [12] [13] These four CB studies showed an advantage of transplantation of cultured CB CD34
þ cells compared to transplantation of an unmanipulated graft with respect to in vivo platelet formation. In a study where MPB CD34 þ cell-derived MKs were transplanted, delayed and transient platelet formation was observed in NOD/SCID mice, 9 while in our study, human platelets were already detectable 3 days after transplantation of ex vivo generated MKs.
It might be argued that addition of cultured cells can have a negative effect on the formation of other blood cells than 
Figure 1
Human platelet formation in nonobese diabetic/severe combined immunodeficiency mice after transplantation of grafts containing uncultured cells and/or cultured megakaryocytes (MKs). (a) Graph showing the average number of human platelets detected per ml mouse blood7s.e.m. At days 3 and 7 after transplantation human platelets were only detected in the blood of mice receiving cultured cells. In the blood of mice receiving only uncultured cells (group 1) human platelets were detected from day 10 on. (b) Box plot showing the number of human platelets per ml blood of the mice from all the groups at day 3. The mice from groups 1 and 2 did not show detectable numbers of human platelets. All mice receiving more than 10% expanded MKs (groups 3-5) showed significantly higher human platelet levels than did mice of groups 1 and 2. (c) Box plot depicting human platelet numbers at day 14. Mice that received only expanded MKs (group 5) showed significantly lower human platelet numbers per ml blood than mice from groups 1-3. The statistical differences in platelet formation between groups were calculated with the non-parametric Wilcoxon-Mann-Whitney test. Differences were considered significant when Po0.05. Letters to the Editor platelets. However, our results show that co-transplantation of expanded MKs did not significantly alter the extent of human engraftment or the lineage distribution at 5 weeks posttransplant in the mouse BM, spleen or blood (Supplementary Figure 2) . Besides, in the clinical trials with ex vivo generated MKs published so far, only positive effects on neutrophil recovery and no negative effect on other blood cell lineages were observed. [1] [2] [3] [4] Together, these data indicate that the addition of ex vivo generated MKs to the transplant does not influence the engraftment potential, engraftment pattern or the differentiation capacity of the unmanipulated CD34 þ cells in various mouse organs.
To investigate whether similar results of short-term platelet formation in NOD/SCID mice can be obtained with a shorter culture period, cells were cultured overnight, 4 or 7 days in the presence of 100 ng ml À1 Tpo and 10 ng ml À1 IL-1b, to obtain different MK (progenitor) populations (Figure 2a) . In the overnight culture, cells were lost (proliferation factor of 0.77), but the percentage of CD34 þ CD41 þ cells increased from 2.8% in the uncultured population to 10.9% after overnight culture. After 4 days, cell numbers had increased 1.9-fold, and 26.5% of the cell population consisted of CD34 þ CD41 þ cells. After 7 days of culture, cells had expanded 7.9-fold. The percentage of CD34 þ CD41 þ cells at that time was 56.3%, and in this culture a significant proportion of the cells was CD34 À CD41 þ (12.7%). The cells from these cultures were harvested and subsequently intravenously transplanted in sublethally irradiated NOD/SCID mice according to the dosing scheme depicted in Table 2 . Human platelet formation was again monitored for several weeks. Three days after transplantation, more human platelets were detected in the blood of mice of group D (7-day culture) as compared to the other groups (Figure 2b) . The average platelet level in groups A-C was 0.39 Â 10 4 , 1.4 Â 10 4 and 1.5 Â 10 4 per ml, respectively, while it was 6.4 Â 10 4 ml À1 in group D. This difference still existed at day 7 after transplantation. It should be noted that at this time group C (4-day culture) had a mean platelet number of 8.5 Â 10 4 ml À1 , which is comparable to the number detected in group D after 3 days (6.4 Â 10 4 ml À1 ). Together, these results show that a shorter culture period results in delayed platelet formation. This implies that a predifferentiation of CD34 þ cells toward the megakaryocyte lineage of at least 7-days is necessary to achieve rapid in vivo platelet formation.
However, since the cell numbers in the graft were based on input numbers in the culture, the total number of cells transplanted varied for each group ( Table 2 ), meaning that the total cell number transplanted was higher for groups receiving cells cultured for a longer period. However, the kinetics of platelet formation in the different groups of mice were comparable, implying that in vivo proliferation and differentiation compensates for the difference in culture time.
Five weeks after transplantation, the mice were sacrificed. The average percentage of human engraftment in the bone marrow was 56.4, 33.5, 15.3 and 8.7% for groups A-D, respectively (Supplementary Figure 3) . Thus, the percentage of CD45 þ cells in the BM of the mice decreased with the culture time of the HPCs. Since equal numbers of input cells in the culture were transplanted, the mice in groups C and D received more CD34 þ cells than the mice in groups A and B ( Table 2 ). The mice in group D received six times more CD34 þ cells than the mice in group A (29.9 Â 10 6 in group D versus 4.5 Â 10 6 in group A), but showed a more than sixfold decrease of human cells in the bone marrow 5 weeks after transplantation (8.7% in group D versus 56.4% in group A). This clearly demonstrates that the cultured cells are less effective in providing long-term engraftment. Similar to the above-described transplantation experiments, the lineage distribution was not influenced by the difference in culture time (CD34 þ see Supplementary  Figure 3 
The observation that the engraftment potential decreased with the culture time, is in contrast with data obtained with CB CD34 þ cells expanded for 10 days in the presence of Tpo. 13 In that study, the total number of CD34 þ cells transplanted was comparable between the non-expanded and the expanded grafts and the percentage of CD45 þ cells in the BM after 6 weeks was slightly higher for the expanded graft compared to the non-expanded graft. The discrepancy with our results may be explained by differences in proliferation and maturation responses of CB and MPB HPCs. 14, 15 Furthermore, in support of our data, it has been suggested that cell surface phenotype might not correlate with engraftment potential after culture. 16 A decade ago, the first feasibility study with MKs generated ex vivo by a 7-day culture protocol with 20 ng ml À1 macrophage inflammatory protein-1p and FLT-ligand, and 10 ng ml À1 interleukin-3 (IL-3), IL-6, IL-11, stem cell factor and megakaryocyte growth and development factor (recombinant Tpo), demonstrated that ex vivo generated MKs can be administered safely and might improve platelet recovery. 1 Less than 10% of the leukapheresis material was used for MK generation. Another clinical study with 10 lymphoma patients showed no positive effect of the addition of MKs, while higher CD61 þ cell numbers were infused. 2 In that study, however, cells were cultured for 10 days in the presence of MGDF and SCF. The longer culture period in this study might well have resulted in more mature, larger and thus possibly more fragile MKs, which might therefore show less efficient homing and platelet production in vivo. In our study, more than 10% of the graft needed to be expanded and differentiated towards MKs to be able to detect platelets as early as 3 days after transplantation.
In terms of feasibility, in most autologous transplantation settings a graft of 4 Â 10 6 CD34 þ cells kg À1 is considered sufficient for full hematopoietic recovery which is normally easily harvested in one leukapheresis procedure. If another portion of 4 Â 10 6 CD34 þ cells kg À1 would be cultured in our 7-day expansion protocol, between À12 Â 10 6 and 18 Â 10 6 CD41 þ cells kg À1 would have to be co-transplanted, making our culture protocol clinically applicable.
To our knowledge, we are the first to demonstrate that MKs generated from MPB CD34 þ cells are able to significantly increase human platelet formation in NOD/SCID mice within the first 10 days following transplantation. The results of this study warrant new clinical trials on the use of ex vivo generated MKs to shorten the period of thrombocytopenia after stem cell transplantation.
